Mylan Recalls Atorvastatin Calcium Tablets Due to Microbial Contamination
Mylan Institutional, Inc. is recalling 1,527 cartons of Atorvastatin Calcium 10 mg tablets due to potential microbial contamination and elevated bioburden.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves microbial contamination with objectionable organisms, which poses a significant health risk consistent with the 'Severe' criteria for significant injury or high-risk contamination.
Plain-English summary
Mylan Institutional, Inc. (d.b.a. UDL Laboratories) is recalling 1,527 cartons of Atorvastatin Calcium Tablets, 10 mg, 100-count Unit Dose Tablets. The product is identified by NDC 51079-208-20, Lot # 3084288, and an expiration date of 07/18. The recall was initiated because of microbial contamination of non-sterile products, specifically the potential for an elevated bioburden with the identification of objectionable organisms.
The affected products were distributed nationwide in the USA. This recall is classified as Class II by the U.S. Food and Drug Administration. Consumers and healthcare providers should stop using the affected lot of Atorvastatin Calcium tablets and contact their healthcare provider for alternative treatment options or to return the product to the pharmacy for a refund.
The recalled product
- Product
- ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM)
- Brand
- ATORVASTATIN CALCIUM
- Category
- Drug — Prescription Drug
- Affected units
- 1,527
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 3084288
- Exp. 07/18
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ATORVASTATIN CALCIUM
- ModerateAtorvastatin 10 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 80 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 40 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- ModerateAtorvastatin 20 mg tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-22
- HighBiocon Pharma atorvastatin calcium tablets recalled for failed dissolution specifications
FDA (Drugs) · 2025-04-09
Same manufacturer · Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
See all →- HighEsomeprazole magnesium delayed-release capsules recalled for impurity specification failure
FDA (Drugs) · 2022-05-18
- ModerateEsomeprazole Magnesium Delayed-Release Capsules Recalled for Failed Quality Specifications
FDA (Drugs) · 2022-05-18
- SevereMylan Recalls Alprazolam Tablets Due to Elevated Impurity Levels
FDA (Drugs) · 2019-03-27
- LowMylan Recalls Diltiazem HCl Extended-release Capsules Due to Impurities
FDA (Drugs) · 2018-08-29
- ModerateMylan Recalls Loxapine Capsules Due to Cross-Contamination Risk
FDA (Drugs) · 2018-05-30
Same hazard · microbial contamination
See all →- CriticalVictory Medical Center Pharmacy Recalls Glutathione Vials Due to Contamination
FDA (Drugs) · 2026-08-19
- HighMedline Medical Convenience Kits Recalled Due to Potential Bacillus Contamination
FDA (Devices) · 2026-07-29
- HighMedline Convenience Kits Recalled Over Bacillus Contamination
FDA (Devices) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SeverePemetrexed for Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15